Proteomics and metabolomics studies in pigmented villonodular synovitis uncover the regulation of monocyte differentiation by the ADGRE5-NF-κB pathway.

Journal and index pages often block iframe embedding. This reader keeps the evidence details in Orthonotes and leaves the source page one click away.

Abstract

[Indexed for MEDLINE] Conflict of interest statement: Declarations. Ethics approval and consent to participate.: The study received approval from the Ethics Committee on Biomedical Research at West China Hospital, Sichuan University (No. 125 2020-(921)). Informed consent was obtained from all participants before their involvement in the study. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests. 7. Curr Opin Oncol. 2011 Jul;23(4):361-6. doi: 10.1097/CCO.0b013e328347e1e3. Treatment of tenosynovial giant cell tumor and pigmented villonodular synovitis. Ravi V(1), Wang WL, Lewis VO. Author information: (1)Department of Sarcoma Medical Oncology, UT MD Anderson Cancer Center, Houston, Texas 77030, USA. vravi@mdanderson.org PURPOSE OF REVIEW: To review recent developments in the molecular pathogenesis of tenosynovial giant cell tumor (TGCT) or pigmented villonodular synovitis (PVNS) and its therapeutic implications. RECENT FINDINGS: TGCT or PVNS is a benign clonal neoplastic proliferation arising from the synovium characterized by a minor population of intratumoral cells that harbor a recurrent translocation. These cells overexpress CSF1, resulting in recruitment of CSF1R-bearing macrophages that are polyclonal and make up the bulk of the tumor. Inhibition of CSF1R using small molecule inhibitors such as imatinib, nilotinib or sunitinib can result in clinical, radiological and functional improvement in the affected joint. SUMMARY: Currently, surgery remains the treatment of choice for patients with TGCT/PVNS. Localized TGCT/PVNS is managed by marginal excision. Recurrences occur in 8-20% of patients and are easily managed by re-excision. Diffuse TGCT/PVNS tends to recur more often (33-50%) and has a much more aggressive clinical course. Patients are often symptomatic and require multiple surgical procedures during their lifetime. For patients with unresectable disease or multiple recurrences, systemic therapy using CSF1R inhibitors may help delay or avoid surgical procedures and improve functional outcomes. DOI: 10.1097/CCO.0b013e328347e1e3